TMEM106B

Across TCGA pan-cancer cohorts, TMEM106B Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM106B data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TMEM106B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM106B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, HNSC, and CESC are the cancer types where TMEM106B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.090	0.688	<.001	33	view →
HNSC	OS	Median	II,III,IV	0.177	0.672	.004	18	view →
CESC	DFS	Median	All	0.227	0.742	.001	12	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
KIRP	DFS	Median	All	0.178	0.867	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	1.000	0.198	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM106B–BLCA (OS)

Open the BLCA breakdown →